证券代码：600873 证券简称：梅花生物 公告编号：2023-060 梅花生物科技集团股份有限公司 关于股份回购进展情况的公告 公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 梅花生物科技集团股份有限公司（以下简称"公司"）分别于 2023 年 4 月 8 日、2023 年 4 月 28 日召开了第十届董事会第三次会议和 2023 年第二次临时股 东大会，会议审议通过了《关于以集中竞价交易方式回购公司股份的议案》，公 司于 2023 年 4 月 29 日披露了《梅花生物科技集团股份有限公司关于以集中竞价 交易方式回购股份的回购报告书》，本次回购金额不低于人民币 8 亿元，不超过 人民币 10 亿元，回购股份用于注销，减少注册资本。具体内容详见公司披露在 上海证券交易所网站（www.sse.com.cn）上的相关公告。 根据《上海证券交易所上市公司自律监管指引第 7 号—回购股份》等相关法 律法规的要求，公司应在每个月的前 3 个交易日公告截至上月末的回购进展情 况。现将公司回购股份进展的具体情况公告如下： 2023 年 ...

Financial Performance - The company's operating revenue for Q3 2023 was approximately RMB 6.94 billion, representing a year-on-year increase of 5.10%[4] - The net profit attributable to shareholders for Q3 2023 was approximately RMB 789.67 million, a decrease of 9.05% compared to the same period last year[4] - The net profit attributable to shareholders after deducting non-recurring gains and losses for Q3 2023 was approximately RMB 691.98 million, down 19.02% year-on-year[4] - The basic earnings per share for Q3 2023 was RMB 0.27, reflecting a decrease of 3.57% compared to the previous year[4] - The weighted average return on equity for Q3 2023 was 5.54%, a decrease of 1.44 percentage points from the previous year[4] - The total comprehensive income for the third quarter was ¥2,447,973,619.90, compared to ¥3,416,988,074.17 in the previous year, a decrease of about 28.38%[17] - The company's long-term borrowings decreased to ¥2,708,924,876.77 from ¥3,676,011,413.26, a decline of approximately 26.36%[13] - Basic and diluted earnings per share for Q3 2023 were both ¥0.72, compared to ¥1.11 in Q3 2022, indicating a decline of approximately 35.1%[18] Assets and Liabilities - The total assets at the end of Q3 2023 were approximately RMB 24.23 billion, a decrease of 1.05% from the end of the previous year[4] - The equity attributable to shareholders at the end of Q3 2023 was approximately RMB 14.18 billion, an increase of 4.92% compared to the end of the previous year[4] - Total assets decreased to ¥24,233,637,909.60 from ¥24,490,222,471.46, a decline of approximately 1.05%[13] - Total liabilities decreased to ¥10,053,151,691.39 from ¥10,974,089,118.69, a reduction of about 8.36%[13] - The company's fixed assets increased to RMB 11,629,762,535.68 from RMB 9,911,708,010.15, reflecting a growth of approximately 17.31%[12] - The total non-current assets increased to RMB 14,798,946,512.61 from RMB 14,577,638,970.15, showing a growth of approximately 1.52%[12] Cash Flow - The cash flow from operating activities for the year-to-date period decreased by 10.47% compared to the previous year, attributed to reduced sales collections and increased raw material costs[6] - Cash inflow from operating activities for the first nine months of 2023 was ¥22,505,535,051.46, a decrease of about 2.1% from ¥22,997,408,878.67 in the same period of 2022[19] - Net cash flow from operating activities for the first nine months of 2023 was ¥4,884,286,182.54, down 10.5% from ¥5,455,580,471.51 in the previous year[19] - Cash inflow from investment activities for the first nine months of 2023 was ¥29,103,914.50, compared to a cash outflow of ¥34,435,357.45 in the same period of 2022[20] - Net cash flow from investment activities for the first nine months of 2023 was -¥1,453,883,158.21, an improvement from -¥2,531,821,725.50 in the previous year[20] - Cash inflow from financing activities for the first nine months of 2023 was ¥3,597,740,538.77, significantly higher than ¥1,980,634,410.15 in the same period of 2022[20] - Net cash flow from financing activities for the first nine months of 2023 was -¥2,386,027,386.63, an improvement from -¥3,038,275,411.91 in the previous year[20] - The ending balance of cash and cash equivalents as of September 30, 2023, was ¥5,203,814,144.66, up from ¥3,202,289,539.31 at the end of Q3 2022[20] Market and Strategic Developments - The company established a new wholly-owned subsidiary, Zhuhai Hengqin Meihua Biotechnology Co., Ltd., with an investment of RMB 50 million to expand its international market presence[9] - The company plans to set up additional subsidiaries in Hong Kong, Cayman Islands, and Singapore as part of its international expansion strategy[9] - The company has committed to strict compliance with regulations regarding share repurchase and timely information disclosure[9] Revenue and Costs - The company's revenue for the year-to-date period was approximately RMB 20.53 billion, a decrease of 1.42% year-on-year, mainly due to lower prices for key products[6] - Operating revenue for the first three quarters of 2023 was ¥20,526,171,453.75, a slight decline from ¥20,821,165,705.82, reflecting a decrease of about 1.42%[15] - Operating costs increased to ¥18,070,945,779.49 from ¥16,877,698,645.08, an increase of approximately 7.06%[15] - Research and development expenses rose to ¥234,168,723.06 from ¥198,828,242.72, marking an increase of about 17.69%[15] - The company's gross profit margin decreased from 21.79% in the previous year to 18.48% in Q3 2023, primarily due to lower prices for key products and higher corn prices[6]

证券代码：600873 证券简称：梅花生物 公告编号：2023-059 梅花生物科技集团股份有限公司 关于2023年前三季度经营数据公告 3、按地区分： | 地区分布 | 本期营业收入（万元） | | --- | --- | | 国内 | 1,430,563.05 | | 国外 | 622,054.10 | | 合计 | 2,052,617.15 | 特此公告。 1、按产品分： | 产品类别 | 本期营业收入（万元） | | --- | --- | | 鲜味剂（谷氨酸钠、核苷酸） | 657,738.58 | | 饲料氨基酸（赖氨酸、苏氨酸、色氨酸等） | 731,963.85 | | 医药氨基酸（谷氨酰胺、脯氨酸、亮氨酸、异亮氨酸、腺苷等） | 43,241.96 | | 大原料副产品（肥料、蛋白粉、胚芽、玉米皮粉、饲料纤维等） | 369,014.66 | | 其他（黄原胶、海藻糖等） | 250,658.10 | | 合计 | 2,052,617.15 | 2、按销售模式分： | 销售模式 | 本期营业收入（万元） | | --- | --- | | 直销 | 1,210,192.83 | | 代销 | ...

梅花生物科技集团股份有限公司 关于股份回购进展情况的公告 证券代码：600873 证券简称：梅花生物 公告编号：2023-058 梅花生物科技集团股份有限公司董事会 公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 梅花生物科技集团股份有限公司（以下简称"公司"）分别于 2023 年 4 月 8 日、2023 年 4 月 28 日召开了第十届董事会第三次会议和 2023 年第二次临时股 东大会，会议审议通过了《关于以集中竞价交易方式回购公司股份的议案》，公 司于 2023 年 4 月 29 日披露了《梅花生物科技集团股份有限公司关于以集中竞价 交易方式回购股份的回购报告书》，本次回购金额不低于人民币 8 亿元，不超过 人民币 10 亿元，回购股份用于注销，减少注册资本。具体内容详见公司披露在 上海证券交易所网站（www.sse.com.cn）上的相关公告。 根据《上海证券交易所上市公司自律监管指引第 7 号—回购股份》等相关法 律法规的要求，公司应在每个月的前 3 个交易日公告截至上月末的回购进展情 况。现将公司回购股份进展 ...

证券代码：600873 证券简称：梅花生物 公告编号：2023-057 现将公司回购股份进展的具体情况公告如下： 截至 2023 年 9 月 26 日，公司回购股份 41,189,152 股，占公司目前股本总数 (2,943,426,102 股)的 1.40%，购买的最低价格为 8.42 元/股、最高价格为 9.67 元/ 股，支付的总金额为人民币 36,694.75 万元，本次回购符合公司回购方案的要求。 梅花生物科技集团股份有限公司 关于股份回购进展情况的公告 公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 梅花生物科技集团股份有限公司（以下简称"公司"）分别于 2023 年 4 月 8 日、2023 年 4 月 28 日召开了第十届董事会第三次会议和 2023 年第二次临时股 东大会，会议审议通过了《关于以集中竞价交易方式回购公司股份的议案》，公 司于 2023 年 4 月 29 日披露了《梅花生物科技集团股份有限公司关于以集中竞价 交易方式回购股份的回购报告书》，本次回购金额不低于人民币 8 亿元，不超过 人民币 ...

证券代码：600873 证券简称：梅花生物 公告编号：2023-055 梅花生物科技集团股份有限公司 关于召开 2023 年半年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大 遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： https://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 投资者可于 2023 年 09 月 11 日(星期一)至 09 月 15 日(星期五)16:00 前登 录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 mhzqb@meihuagrp.com 进行提问。公司将在说明会上对投资者普遍关注的 问题进行回答。 梅花生物科技集团股份有限公司（以下简称"公司"）已于 2023 年 8 月 19 日发布公司 2023 年半年度报告，为便于广大投资者更全面深入地了解公司 2023 年上半年的经营成果、财务状况，公司计划于 2023 年 09 月 18 日上午 10:00-11:00 举行 2023 年半年度业绩说明会，就投资者关心的问题进行交流。 一、说明会类型 本次投资者说 ...

梅花生物科技集团股份有限公司（以下简称"公司"）分别于 2023 年 4 月 8 日、2023 年 4 月 28 日召开了第十届董事会第三次会议和 2023 年第二次临时股 东大会，会议审议通过了《关于以集中竞价交易方式回购公司股份的议案》，公 司于 2023 年 4 月 29 日披露了《梅花生物科技集团股份有限公司关于以集中竞价 交易方式回购股份的回购报告书》，本次回购金额不低于人民币 8 亿元，不超过 人民币 10 亿元，回购股份用于注销，减少注册资本。具体内容详见公司披露在 上海证券交易所网站（www.sse.com.cn）上的相关公告。 根据《上海证券交易所上市公司自律监管指引第 7 号—回购股份》等相关法 律法规的要求，公司应在每个月的前 3 个交易日公告截至上月末的回购进展情 况。现将公司回购股份进展的具体情况公告如下： 2023 年 8 月，公司通过集中竞价交易方式回购股份 1609.29 万股，占公司目 前股本总数(2,943,426,102 股)的 0.55%，购买的最低价格为 8.42 元/股、最高价格 为 8.94 元/股，支付的总金额为人民币 13,923.00 万元。 截至 2023 ...

Financial Performance - The company's operating revenue for the first half of 2023 was ¥13,588,270,517.23, a decrease of 4.44% compared to ¥14,219,627,182.50 in the same period last year[16]. - The net profit attributable to shareholders of the listed company was ¥1,370,843,964.88, down 46.77% from ¥2,575,258,639.11 in the previous year[16]. - The net cash flow from operating activities was ¥2,270,492,293.32, a decline of 34.52% compared to ¥3,467,226,044.54 in the same period last year[16]. - Basic earnings per share for the first half of 2023 were ¥0.45, down 45.78% from ¥0.83 in the same period last year[17]. - The weighted average return on net assets decreased by 11.91 percentage points to 9.46% from 21.37% in the previous year[17]. - The company reported a net profit excluding non-recurring gains and losses of ¥1,406,493,134.64, a decrease of 44.40% from ¥2,529,570,566.12 in the previous year[16]. - The diluted earnings per share were also ¥0.45, reflecting the same decline of 45.78% compared to the previous year[17]. - The company reported a non-recurring loss of ¥35,649,169.76, primarily due to losses from non-operating income and expenses[18]. - The company achieved a stable revenue performance with key products like xanthan gum and pharmaceutical amino acids driving growth, while feed amino acid product revenue decreased by 16.04% year-on-year to CNY 4.758 billion[32]. Assets and Liabilities - The total assets at the end of the reporting period were ¥24,393,256,825.48, a slight decrease of 0.40% from ¥24,490,222,471.46 at the end of the previous year[16]. - The net assets attributable to shareholders of the listed company increased by 5.46% to ¥14,254,255,752.16 from ¥13,516,133,352.77 at the end of the previous year[16]. - The asset-liability ratio at the end of the reporting period was 41.56%, a decrease of 3.25 percentage points from the beginning of the period[31]. - The company's total liabilities were CNY 10,139,001,073.32, down from CNY 10,974,089,118.69, reflecting a decrease of approximately 7.6%[99]. - The total non-current assets increased to CNY 15,553,053,774.35 from CNY 14,577,638,970.15, reflecting an increase of approximately 6.7%[99]. Market and Product Development - The company specializes in amino acid products, including lysine, threonine, tryptophan, and glutamic acid, with a focus on animal nutrition and food flavor optimization[20]. - The company has achieved a full-chain upgrade in synthetic biology, from genome editing to product implementation, enhancing its competitive edge in the industry[20]. - The company is focused on expanding its market presence and enhancing its product portfolio through research and development initiatives[20]. - The company anticipates a continued increase in demand for amino acids due to the reduction of soybean meal in feed formulations, with a target reduction of 0.5 percentage points per year until it reaches below 13% by 2025[23]. - The company is expanding production capacity with new projects, including the Jilin xanthan gum project, which achieved full production in June 2023, enhancing competitive strength[34]. Research and Development - The company applied for 25 new patents in the first half of the year, enhancing its intellectual property portfolio[26]. - Research and development expenses increased to CNY 149,290,010.79 in the first half of 2023, up from CNY 124,531,311.23 in the previous year, marking a growth of 19.8%[105]. - The company has invested in advanced equipment, such as next-generation genome sequencers, to facilitate high-throughput screening and product development[20]. Environmental and Safety Management - The company has implemented safety management measures to mitigate risks associated with production accidents[48]. - The company has invested approximately 200 million yuan in boiler flue gas treatment systems, achieving emissions that are significantly below national standards[61]. - The company has established emergency response plans for environmental pollution incidents, which are filed with local environmental authorities[65]. - The company has faced two environmental administrative penalties due to exceeding odor concentration limits at the factory boundary[67]. Shareholder and Governance Matters - The company did not propose any profit distribution plan or capital reserve transfer to increase share capital during this reporting period[3]. - The company completed a share buyback of 450 million yuan in the first half of 2023, reflecting confidence in its future development[31]. - The company’s actual controller and related parties have committed to avoiding any business that may compete with the company’s main operations during their control period, which has been strictly adhered to since July 19, 2010[77]. - The company has not engaged in any non-operating fund occupation by controlling shareholders or related parties during the reporting period[78]. Financial Instruments and Accounting Policies - The company classifies financial assets into three categories: those measured at amortized cost, those measured at fair value with changes recognized in other comprehensive income, and those measured at fair value with changes recognized in profit or loss[136]. - Financial assets measured at amortized cost include cash, certain receivables, and debt investments, with interest income recognized using the effective interest method[137]. - The company recognizes impairment for financial assets measured at amortized cost and those classified as fair value through other comprehensive income[143]. - The company assesses expected credit losses for accounts receivable based on historical loss experience and current conditions, predicting future economic conditions[152]. Future Outlook - The company expects revenue growth to continue, projecting a 20% increase for the second half of 2023[131]. - The company plans to focus on new product development and market expansion strategies in the upcoming quarters[102].

证券代码：600873 证券简称：梅花生物 公告编号：2023-051 梅花生物科技集团股份有限公司（以下简称"公司"）第十届董事会第五次会 议于 2023 年 8 月 18 日以现场方式召开，会议应出席董事 5 人，实际出席董事 5 人，会议由董事长王爱军女士主持，公司监事和高级管理人员列席了会议。本次 会议的召开符合《公司法》和《公司章程》的规定。 二、会议审议情况 经出席本次会议的全体董事审议，以投票表决方式全票通过以下议案： 梅花生物科技集团股份有限公司 第十届董事会第五次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 一、会议召开情况 近年来公司业务规模不断扩大，现有架构设定无法满足日益增长的海外市场 需求，为进一步满足公司拓展国际市场、布局国际贸易和实体业务发展的需要， 公司拟在横琴设立全资子公司。新公司拟定名为横琴梅花控股有限公司（简称"横 琴公司"），法定代表人王爱军，公司类型为有限责任公司（法人独资），出资方 式为货币出资，资金来源为自有资金，经营范围拟定为生物氨基酸产品及其他产 品的生产 ...

证券代码：600873 证券简称：梅花生物 公告编号：2023-052 梅花生物科技集团股份有限公司 关于2023年半年度经营数据公告 公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 3、按地区分： | 地区分布 | 本期营业收入（万元） | | --- | --- | | 国内 | 939,772.42 | | 国外 | 419,054.63 | | 合计 | 1,358,827.05 | 特此公告。 根据《上市公司行业信息披露指引第十四号—食品制造》第十四条、《关于 做好主板上市公司 2023 年半年度报告披露工作的重要提醒》的要求，现将梅花 生物科技集团股份有限公司 2023年半年度经营数据（未经审计）公告如下： 1、按产品分： | 产品类别 | 本期营业收入（万元） | | --- | --- | | 鲜味剂（谷氨酸钠、核苷酸） | 444,567.07 | | 饲料氨基酸（赖氨酸、苏氨酸、色氨酸等） | 475,820.72 | | 医药氨基酸（谷氨酰胺、脯氨酸、亮氨酸、异亮氨酸、腺苷等） | 29,991.59 ...